Conjugates of biologically stable polymers and polynucleotides for treating systemic lupus erythematosus
US5162515A · kind A · utility
24Cited by
3References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 13, 1990 |
| Grant date | Nov 10, 1992 |
| Priority date | — |
| Expiry date | Mar 13, 2010 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/6093
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Chemically defined conjugates of biologically stable polymers, such as copolymers of D-glutamic acid and D-lysine, and polynucleotide duplexes of at least 30 base pairs that have significant binding activity for human lupus anti-dsDNA autoantibodies. The duplexes are preferably homogeneous in length and structure and are bound to the polymer via reaction between an amino-reactive functional group located at or proximate a terminus of each duplex. These conjugates are tolerogens for human systemic lupus erythematosus.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.